Volvo EX90 Electric SUV Will Feature Seoul Semiconductor’s SunLike LED Lighting
18.4.2023 16:00:00 EEST | Business Wire | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ:046890), a global optical semiconductor company, has announced that the new Volvo EX90 Electric SUV will feature its SunLike LED lights. This is the first application of the SunLike technology with sun spectrum in production vehicles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230418005618/en/
Volvo EX90 featuring the SunLike technology (Left) / Comparative graph of color gamuts between SunLike and general LEDs (Right) (Graphic: Business Wire)
SunLike, developed and mass-produced by Seoul Semiconductor for the first time in the world, is a healthy light technology that replicates natural light, protecting the 24-hour biological cycle of a human body. For the past five years, Seoul Semiconductor carried out multiple clinical trials with Harvard University in the United States, the University of Basel in Switzerland, and Seoul National University in Korea, confirming that the use of the solar spectrum, SunLike, can make improvements in myopia, regenerate cells, improve memory, and replicate natural colors.
NEARSIGHTEDNESS IMPROVEMENT
Not all lights are the same, and not all lightings are the same. The closer it is to natural light, the better it is. Light is a mass of particles with energy, so the longer our eyes are exposed to high levels of blue light with high energy, there is a greater chance of damaging our photoreceptor cells and developing myopia. This is why children in Asia who spend more time indoors than outdoors under natural light have a high prevalence of myopia.
According to the “Recovery From Form-Deprivation Myopia in Chicks Is Dependent Upon the Fullness and Correlated Color Temperature of the Light Spectrum(2020)” by Singapore Eye Research Institute (SERI), myopia can be improved by using SunLike.
CELL REPRODUCTION
Natural light affects sleep as well. Evening sunlight promotes the secretion of melatonin which helps to sleep. They say more than 70% of our 60 trillion body cells regenerate while we sleep. Seoul Semiconductor confirmed through the “Effect of daylight LED on visual comfort, melatonin, mood, waking performance and sleep (2019)” conducted by the University of Basel in Switzerland that SunLike lighting improves sleep quality compared to conventional LEDs.
MEMORY IMPROVEMENT
Getting a good night sleep reduces the possibility of building up toxins in the brain, improving memory and concentration. Seoul Semiconductor confirmed through the “Daytime Exposure to Short Wavelength-Enriched Light Improves Cognitive Performance in Sleep-Restricted College-Aged Adults (2021)” conducted by Harvard Medical School that problem-solving skills improved by 5% and speed increased by 3.2 folds when SunLike lighting was used.
COLOR REPLICATION
Conventional LED with CRI 90 have a 90% color gamut of 14 colors in high CRI 90 (sunlight 100). However, SunLike has a 95% color gamut of all 99 colors. This means that it is closest to the color seen under natural sunlight.
According to Dan Fidgett, Volvo’s head of materials and colors, “By utilising the spectrum of light emitted from the SunLike LEDs, the progressive materials and interior design of the Volvo EX90 stand out more clearly and without colour distortion” Fidgett also added, “Bringing in SunLike LEDs to the interior of the Volvo EX90 is another illustration of our ambition to bring in innovative technology to deliver a renewed premium in-car experience for our customers”.
For all interior light fixtures of Volvo EX90, SunLike will be installed. Already widely used by large museums and art galleries around the world, SunLike LEDs have been used to reveal the color and texture of Pompeii ruins’ murals in Italy.
N. Kobayashi, SunLike’s key developer and Seoul Semiconductor’s technical advisor (former CEO of TMAT), explains, “SunLike is a differentiated, high-quality ‘healthy lighting’ that has all the benefits of natural light. It is widely being used in various places, such as residential spaces where people rest, hospitals that lack outdoor activities, schools where concentration and vision health are important, horticultural greenhouses that require light, etc”.
In addition to Volvo EX90, SunLike will also equip ‘Polestar 3’ which shares the same technology base.
About Seoul Semiconductor
Seoul Semiconductor is the world’s second-largest global LED manufacturer, a ranking excluding the captive market, and has more than 18,000 patents. Based on a differentiated product portfolio, Seoul offers a wide range of technologies, and mass produces innovative LED products for indoor and outdoor lighting, automotive, IT products, such as mobile phones, computer displays, and other applications, as well as the UV area. Seoul’s world’s first development and mass production products are becoming the LED industry standard and leading the global market with a package-free LED, WICOP; a high-voltage AC-driven LED, Acrich; an LED with 10X the output of a conventional LED, nPola; a cutting edge ultraviolet clean technology LED, Violeds; an all-direction light emitting technology, filament LED; a natural sun spectrum LED, SunLike; and more. For more information, please visit www.seoulsemicon.com/en, YouTube, LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230418005618/en/
Contact information
Seoul Semiconductor Co., Ltd.
Jinseop Jung
+82-1566-2771
jjs8732@seoulsemicon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
